Market Pulse Archives

Oct. 30, 2019, 9:25 a.m. EDT

Cyclerion's stock plummets to pace premarket losers after diabetes treatment study missed primary endpoint

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Cyclerion Therapeutics Inc. (CYCN)
  • X
    iShares Biotechnology ETF (IBB)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Shares of Cyclerion Therapeutics Inc. /zigman2/quotes/207301221/composite CYCN -1.88% plummeted 71% toward a record low Wednesday, to pace all premarket losers, after the biopharmaceutical company said a Phase 2 trial of its diabetes treatment missed the primary endpoint. The company said the Phase 2 proof-of-concept study of praliciguat, which is a once-daily, orally available stimulator in diabetic nephropathy did not meet statistical significance on its primary endpoint of reduction in albuminuria from baseline as compared with placebo. The company said, however, there was a trend toward improvement and improvements were observed in patients in several secondary measures associated with cardiovascular risk and kidney disease. Cyclerion said it still expects to "out-license" praliciguat for global development and commercialization. The stock, which went public in March, has run up 39.2% over the past three months through Tuesday, while the iShares Nasdaq Biotechnology ETF /zigman2/quotes/206189322/composite IBB +0.52% has gained 1.0% and the S&P 500 /zigman2/quotes/210599714/realtime SPX +1.29% has edged up 0.8%.

US : U.S.: Nasdaq
$ 0.69
-0.01 -1.88%
Volume: 48,162
Feb. 7, 2023 3:59p
P/E Ratio
Dividend Yield
Market Cap
$30.36 million
Rev. per Employee
US : U.S.: Nasdaq
$ 136.32
+0.71 +0.52%
Volume: 1.41M
Feb. 7, 2023 4:15p
+52.92 +1.29%
Volume: 0.00
Feb. 7, 2023 5:00p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.